Methyl 5-cyclohexyl-7-oxo-7 H-thieno[3,2-b ]pyran-3-carboxylate | 324741-21-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: Methyl 5-cyclohexyl-7-oxo-7 H-thieno[3,2-b ]pyran-3-carboxylate
• 英文别名: Methyl 5-cyclohexyl-7-oxo-7H-thieno[3,2-b]pyran-3-carboxylate；methyl 5-cyclohexyl-7-oxothieno[3,2-b]pyran-3-carboxylate
• CAS: 324741-21-1
• 化学式: C₁₅H₁₆O₄S
• 分子量: 292.356
• InChiKey: PIBCOIPCWBQVOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  80.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1,4-二氧六环 、 Methyl 5-cyclohexyl-7-oxo-7 H-thieno[3,2-b ]pyran-3-carboxylate 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 以0.028 g (73.5%)的产率得到5-Cyclohexyl-7-oxo-5-phenyl-7H-thieno[3,2-b]pyran-3-carboxylic acid
  参考文献：
  名称：

  Thienopyrancecarboxamide derivatives

  摘要：

  该发明涉及以下式I的化合物： 其中R是芳基、环烷基或多卤代烷基基团，R1选择自烷基、烷氧基、多氟烷氧基、羟基和三氟甲磺氧基组成的群；R2和R3中的每一个独立地选择自氢、卤素、烷氧基和多氟烷氧基组成的群，n为0、1或2。 该发明还提供了包含式I的化合物或该化合物的N-氧化物或药用上可接受的盐与药用可接受的稀释剂或载体混合的药物组合物。 在另一个方面，本发明涉及通过给予需要这种治疗的哺乳动物（包括人类）有效用于特定用途的量或多量的选择性地预防尿道和下泌尿道的收缩的方法，该方法不会显著影响血压。 在另一个方面，该发明涉及通过将该发明的化合物的有效量传递给该受体的环境，例如，对细胞外介质进行传递（或通过给予具有该受体的哺乳动物）的方法，从而缓解与该受体过度活跃相关的疾病的方法。 本发明的目的还在于提供一种治疗BPH的方法，该方法避免由于急性低血压而产生的任何不适当的副作用（即，对血压的影响有限）。 本发明的另一个目的是提供包括7-氧代-7H-噻吩[3,2-b]吡喃化合物的药物组合物，这些化合物是选择性的α1肾上腺素受体拮抗剂，该组合物对于治疗BPH是有效的，可选地包括载体或稀释剂。 本发明的另一个目的是提供使用选择性α1肾上腺素受体拮抗剂7-氧代-7H-噻吩[3,2-b]吡喃化合物治疗BPH的方法。 该发明的其他方面包括使用新化合物降低眼内压、治疗心律失常和勃起功能障碍、治疗交感介导的疼痛、治疗NLUTD以及男性和女性的LUTS的治疗。 在该发明的另一个方面，该发明的化合物与抗胆碱药物结合给予。

  公开号：

  US06306861B1

文献信息

• Thienopyranecarboxamide derivatives
  申请人：Recordati S.A. Chemical and Pharmaceutical Company

  公开号：US20020193381A1

  公开（公告）日：2002-12-19

  The invention is directed to compounds of Formula I: 1 wherein R is an aryl, cycloalkyl or polyhaloalkyl group, R 1 is chosen from the group consisting of alkyl, alkoxy, polyfluoroalkoxy, hydroxy and trifluoromethanesulfonyloxy; each of R 2 and R 3 independently is chosen from the group consisting of a hydrogen, halogen, alkoxy and polyfluoroalkoxy group, and n is 0, 1 or 2. The invention further provides pharmaceutical compositions comprising a compound of Formula I or a N-oxide or pharmaceutically acceptable salt of such a compound in admixture with a pharmaceutically acceptable diluent or carrier. In another aspect, the present invention is directed to methods for selectively preventing contractions of the urethra and lower urinary tract, without substantially affecting blood pressure, by administering one or more selected compounds of Formula I to a mammal (including a human) in need of such treatment in an amount or amounts effective for the particular use. In yet another aspect, the invention is directed to methods for blocking &agr; 1 receptors, by delivering to the environment of said receptors, e.g., to the extracellular medium, (or by administering to a mammal possessing said receptors) an effective amount of a compound of the invention, in this way relieving diseases associated to overactivity of said receptors. It is also an object of the present invention to provide a method of treating BPH which avoids any undue side effects due to acute hypotension (i.e., limited effects on blood pressure). It is another object of the present invention to provide pharmaceutical compositions comprising 7-oxo-7H-thieno[3,2-b] pyran compounds which are selective &agr; 1 adrenoceptor antagonists, which compositions are effective for the treatment of BPH optionally including a carrier or diluent. It is another object of the present invention to provide a method of treating BPH using 7-oxo-7H-thieno[3,2-b] pyran compounds which are selective &agr; 1 adrenoceptor antagonists. Other aspects of the invention are the use of new compounds for lowering intraocular pressure, the treatment of cardiac arrhythmia and erectile dysfunction, treatment of sympathetically mediated pain, treatment of NLUTD, and treatment of LUTS in males and females. In another aspect of the invention, compounds of the invention are administered in combination with anticholinergic compounds.

  本发明涉及式I的化合物：1其中R是芳基，环烷基或多卤代烷基，R1选择自烷基，烷氧基，多氟烷氧基，羟基和三氟甲烷磺酰氧基的群，R2和R3各自独立地选择自氢，卤素，烷氧基和多氟烷氧基的群，n为0、1或2。本发明还提供了含有式I化合物或该化合物的N-氧化物或药学上可接受的盐与药学上可接受的稀释剂或载体混合的制药组合物。在另一个方面，本发明是通过向需要此类治疗的哺乳动物（包括人类）中投与一种或多种选择的式I化合物的数量有效地选择性地预防尿道和下泌尿道收缩，而不会对血压产生实质性影响的方法。在另一个方面，本发明是通过向&agr;1受体的环境中传递有效量的本发明化合物（例如，向细胞外介质中传递或向具有该受体的哺乳动物中给药），从而缓解与该受体过度活跃相关的疾病的方法。本发明的另一个目的是提供一种治疗BPH的方法，该方法避免了由于急性低血压而产生的任何不适当的副作用（即，对血压的影响有限）。本发明的另一个目的是提供包括7-氧代-7H-噻吩[3,2-b]吡喃化合物的制药组合物，该组合物是选择性&agr;1肾上腺素受体拮抗剂，可用于治疗BPH，可选地包括载体或稀释剂。本发明的另一个目的是提供使用7-氧代-7H-噻吩[3,2-b]吡喃化合物的方法，该化合物是选择性&agr;1肾上腺素受体拮抗剂，用于治疗BPH。本发明的其他方面是使用新化合物降低眼压，治疗心律失常和勃起功能障碍，治疗交感神经介导的疼痛，治疗NLUTD以及治疗男性和女性的LUTS。在本发明的另一个方面，本发明化合物与抗胆碱药物复合使用。
• THIENOPYRANECARBOXAMIDE DERIVATIVES
  申请人：RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a.

  公开号：EP1200445B1

  公开（公告）日：2003-09-17
• US6306861B1
  申请人：——

  公开号：US6306861B1

  公开（公告）日：2001-10-23
• US6387909B1
  申请人：——

  公开号：US6387909B1

  公开（公告）日：2002-05-14
• Thienopyrancecarboxamide derivatives
  申请人：Recordati S.A. Chemical and Pharmaceutical Company

  公开号：US06306861B1

  公开（公告）日：2001-10-23

  The invention is directed to compounds of Formula I: wherein R is an aryl, cycloalkyl or polyhaloalkyl group, R1 is chosen from the group consisting of alkyl, alkoxy, polyfluoroalkoxy, hydroxy and trifluoromethanesulfonyloxy; each of R2 and R3 independently is chosen from the group consisting of a hydrogen, halogen, alkoxy and polyfluoroalkoxy group, and n is 0, 1 or 2. The invention further provides pharmaceutical compositions comprising a compound of Formula I or a N-oxide or pharmaceutically acceptable salt of such a compound in admixture with a pharmaceutically acceptable diluent or carrier. In another aspect, the present invention is directed to methods for selectively preventing contractions of the urethra and lower urinary tract, without substantially affecting blood pressure, by administering one or more selected compounds of Formula I to a mammal (including a human) in need of such treatment in an amount or amounts effective for the particular use. In yet another aspect, the invention is directed to methods for blocking &agr;1 receptors, by delivering to the environment of said receptors, e.g., to the extracellular medium, (or by administering to a mammal possessing said receptors) an effective amount of a compound of the invention, in this way relieving diseases associated to overactivity of said receptors. It is also an object of the present invention to provide a method of treating BPH which avoids any undue side effects due to acute hypotension (i.e., limited effects on blood pressure). It is another object of the present invention to provide pharmaceutical compositions comprising 7-oxo-7H-thieno[3,2-b]pyran compounds which are selective &agr;1 adrenoceptor antagonists, which compositions are effective for the treatment of BPH optionally including a carrier or diluent. It is another object of the present invention to provide a method of treating BPH using 7-oxo-7H-thieno[3,2-b]pyran compounds which are selective &agr;1 adrenoceptor antagonists. Other aspects of the invention are the use of new compounds for lowering intraocular pressure, the treatment of cardiac arrhythmia and erectile dysfunction, treatment of sympathetically mediated pain, treatment of NLUTD, and treatment of LUTS in males and females. In another aspect of the invention, compounds of the invention are administered in combination with anticholinergic compounds.

  该发明涉及以下式I的化合物： 其中R是芳基、环烷基或多卤代烷基基团，R1选择自烷基、烷氧基、多氟烷氧基、羟基和三氟甲磺氧基组成的群；R2和R3中的每一个独立地选择自氢、卤素、烷氧基和多氟烷氧基组成的群，n为0、1或2。 该发明还提供了包含式I的化合物或该化合物的N-氧化物或药用上可接受的盐与药用可接受的稀释剂或载体混合的药物组合物。 在另一个方面，本发明涉及通过给予需要这种治疗的哺乳动物（包括人类）有效用于特定用途的量或多量的选择性地预防尿道和下泌尿道的收缩的方法，该方法不会显著影响血压。 在另一个方面，该发明涉及通过将该发明的化合物的有效量传递给该受体的环境，例如，对细胞外介质进行传递（或通过给予具有该受体的哺乳动物）的方法，从而缓解与该受体过度活跃相关的疾病的方法。 本发明的目的还在于提供一种治疗BPH的方法，该方法避免由于急性低血压而产生的任何不适当的副作用（即，对血压的影响有限）。 本发明的另一个目的是提供包括7-氧代-7H-噻吩[3,2-b]吡喃化合物的药物组合物，这些化合物是选择性的α1肾上腺素受体拮抗剂，该组合物对于治疗BPH是有效的，可选地包括载体或稀释剂。 本发明的另一个目的是提供使用选择性α1肾上腺素受体拮抗剂7-氧代-7H-噻吩[3,2-b]吡喃化合物治疗BPH的方法。 该发明的其他方面包括使用新化合物降低眼内压、治疗心律失常和勃起功能障碍、治疗交感介导的疼痛、治疗NLUTD以及男性和女性的LUTS的治疗。 在该发明的另一个方面，该发明的化合物与抗胆碱药物结合给予。